{
  "paper_id": "12085592",
  "source_pdf": "gs://patient-engagement-pipeline-bucket/uploads/regulating_the_ai-enabled_ecosystem_for_human_therapeutics.html",
  "fields": [
    {
      "name": "Title",
      "description": "Full title of the study as stated in the paper",
      "value": "Regulating the AI-enabled ecosystem for human therapeutics",
      "evidence_quote": "\"Regulating the AI-enabled ecosystem for human therapeutics\"",
      "page_number": null
    },
    {
      "name": "Author(s)",
      "description": "List of all authors involved in the paper, in order of appearance",
      "value": "Rominder Singh, Mark Paxton, Jared Auclair",
      "evidence_quote": "\"Rominder Singh, Mark Paxton, Jared Auclair\"",
      "page_number": null
    },
    {
      "name": "Patient Co-authors",
      "description": "Were any co-authors identified as patients or caregivers?",
      "value": "No",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Journal",
      "description": "Name of the journal where the study was published",
      "value": "Communications Medicine",
      "evidence_quote": "\"Communications Medicine\"",
      "page_number": null
    },
    {
      "name": "Publication Stage",
      "description": "Indicate if the paper is peer-reviewed, a preprint, or another stage",
      "value": "Peer-reviewed",
      "evidence_quote": "\"Peer review information\"",
      "page_number": 11
    },
    {
      "name": "Publication Date",
      "description": "Official date the paper was published",
      "value": "2025 May 17",
      "evidence_quote": "\"2025 May 17\"",
      "page_number": null
    },
    {
      "name": "Field of Study",
      "description": "Disciplinary or clinical field, such as primary care, oncology, or public health",
      "value": "Regulatory Sciences, Artificial Intelligence, Biopharmaceutical Industry",
      "evidence_quote": "\"Regulatory Sciences & AI\"",
      "page_number": 2
    },
    {
      "name": "Country",
      "description": "Country or countries where the study was conducted or primarily situated",
      "value": "USA",
      "evidence_quote": "\"Boston, MA 02115 USA\"",
      "page_number": 2
    },
    {
      "name": "Type of Article",
      "description": "Classify the article: original research, protocol, review, commentary, etc.",
      "value": "Perspective",
      "evidence_quote": "\"This Perspective examines the challenges of regulating AI-driven technologies in drug discovery and development.\"",
      "page_number": 2
    },
    {
      "name": "Aim of Study",
      "description": "State the main purpose or objective of the study as described by the authors",
      "value": "To examine the challenges of regulating AI-driven technologies in drug discovery and development, evaluate current global drug regulatory practices, discuss gaps and unknowns, and provide recommendations to address these issues.",
      "evidence_quote": "\"This Perspective examines the challenges of regulating AI-driven technologies in drug discovery and development. As AI is anticipated to play an unprecedented role in transforming drug development, the critical question is not whether to regulate these advancements but how to do so effectively. Here, we evaluate current global drug regulatory practices, discuss gaps and unknowns, and provide recommendations on addressing these issues to facilitate effective regulations of AI-driven innovation in the biopharmaceutical industry.\"",
      "page_number": 2
    },
    {
      "name": "Key Findings",
      "description": "Summarize the main results or conclusions of the study",
      "value": "The study highlights the need for robust regulatory oversight of AI-driven technologies in drug development, identifies shortcomings in the current AI-enabled ecosystem, and recommends strategies for regulators to adapt to the increasing role of AI in creating new medicines.",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Patient/Public Engagement (Y/N)",
      "description": "Does the study report any meaningful or intentional involvement of patients or the public in any phase of the research or implementation?",
      "value": "No",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Type of Engagement (Montreal Model continuum)",
      "description": "Categorize engagement based on the Montreal Model: Information (e.g., newsletters), Consultation (e.g., surveys, focus groups), Collaboration (e.g., co-design sessions), or Partnership (e.g., decision-making roles, advisory boards).",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Level of Patient Involvement (Montreal Model)",
      "description": "At what level were patients or the public involved across the research lifecycle? Score each phase (design, development, evaluation, implementation) as: None, Information, Consultation, Collaboration, or Partnership.",
      "value": "None",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Evaluation of Impact (Y/N)",
      "description": "Did the study evaluate or measure the effect of patient/public engagement?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Type of Evaluation",
      "description": "What type of method or framework was used to evaluate the impact of engagement (e.g., metrics, qualitative feedback, evaluation framework)?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Impact of Engagement",
      "description": "Describe any outcomes or changes attributed to patient/public engagement (e.g., design changes, improved recruitment, insights).",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Participatory Process",
      "description": "Did the study include a participatory design process such as workshops, co-design, or stakeholder sessions?",
      "value": "No",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Continuous Evaluation Cycles",
      "description": "Was engagement conducted iteratively or cyclically, with feedback loops or repeated interaction?",
      "value": "No",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Implementation",
      "description": "Did patient/public engagement influence the implementation strategy or process of the research?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Organization of Health Care",
      "description": "Did engagement lead to reported changes in health care delivery, systems design, or institutional practice?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Persuasive Design Techniques",
      "description": "Were behavior-change strategies or persuasive technologies mentioned (e.g., nudges, gamification, reminders)?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Assess Impact",
      "description": "Did the study measure outcomes or success metrics related specifically to engagement efforts?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Information",
      "description": "Was information provided to patients/public about the study, without involving them in decision-making?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Consultation",
      "description": "Was patient or public input sought (e.g., through interviews, surveys, focus groups), without involving them in decision-making?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Collaboration",
      "description": "Was there shared decision-making or co-design between researchers and participants in any phase of the study?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Partnership",
      "description": "Were patients/public involved across all stages with formal roles (e.g., co-authors, advisory board, project governance)?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    },
    {
      "name": "Equity or Inclusivity Considerations",
      "description": "Did the study aim to include marginalized or underrepresented groups in the engagement process?",
      "value": "Yes, the study mentions the importance of addressing data biases in AI to ensure equitable outcomes in healthcare.",
      "evidence_quote": "\"In the development of AI-assisted human therapeutics, data biases in AI can lead to inequitable outcomes, such as underrepresenting diverse populations in clinical trial data or safety analyses. These biases can result in suboptimal therapeutic recommendations, incomplete labeling, or regulatory delays, as regulators may require additional data to ensure safety and efficacy across all patient groups\"",
      "page_number": 5
    },
    {
      "name": "Ethical, Legal, and Social Implications (ELSI)",
      "description": "Did the study address privacy, informed consent, data ethics, or cultural relevance in its engagement or implementation approach?",
      "value": "Yes, the study discusses data privacy, security, informed consent, and liability for AI-related errors.",
      "evidence_quote": "\"Ethical and legal considerations, such as obtaining informed consent for data use and determining liability for AI-related errors, are also essential to address in the responsible implementation of AI\"",
      "page_number": 6
    },
    {
      "name": "Technology Complexity / Integration Readiness",
      "description": "Did the study evaluate how complex the technology was or how well it integrated with existing clinical or community workflows?",
      "value": "Yes, the study acknowledges the \"black box\" nature of many AI models and the need for interpretable outputs.",
      "evidence_quote": "\"Additionally, the \u201cblack box\u201d nature of many AI models means their decision-making processes are not easily interpretable, undermining confidence and complicating clinical decision-making, particularly for regulators.\"",
      "page_number": 6
    },
    {
      "name": "Real-World Evaluation or Deployment",
      "description": "Was the technology evaluated or deployed in real-world settings beyond pilot studies or lab prototypes?",
      "value": "Yes, the study discusses the use of AI in optimizing clinical trials and the deployment of SaMD.",
      "evidence_quote": "\"AI\u2019s impact is not limited to drug discovery or repurposing older therapies. It can also be used to optimize clinical trials, which can bring new biotherapeutics to patients faster\"",
      "page_number": 3
    },
    {
      "name": "Feedback and Iterative Adaptation",
      "description": "Was feedback from participants used in an ongoing way to adapt the design, strategy, or evaluation?",
      "value": "N/A",
      "evidence_quote": "N/A",
      "page_number": null
    }
  ]
}